<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954588</url>
  </required_header>
  <id_info>
    <org_study_id>NL51023.068.16</org_study_id>
    <nct_id>NCT02954588</nct_id>
  </id_info>
  <brief_title>Effect of Pyridoxamine Supplementation on Vascular Function and Insulin Sensitivity</brief_title>
  <official_title>The Effect of Pyridoxamine Supplementation on Vascular Function and Insulin Sensitivity; a Double-blind Randomized Placebo Controlled Trial in Abdominally Obese Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Top Institute Food and Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Translational Molecular Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <brief_summary>
    <textblock>
      A growing body of evidence demonstrates that increased adipose mass, especially visceral&#xD;
      adipose tissue, contributes directly towards an increase in systemic inflammation,&#xD;
      (micro-)vascular dysfunction and the burden of cardiovascular disease (CVD), insulin&#xD;
      resistance and type 2 diabetes. Advanced glycation/lipoxidation endproducts (AGEs/ALEs) are a&#xD;
      heterogeneous family of unavoidable by-products, which are formed by reactive metabolic&#xD;
      intermediates derived from glucose and lipid oxidation. In addition to the overwhelming&#xD;
      amount of data demonstrating the role of AGEs/ALEs in the development of (micro-)vascular&#xD;
      dysfunction and disease, accumulation of AGEs/ALEs in the expanding adipose tissue&#xD;
      contributes to the dysregulation of adipokines and the development of insulin resistance.&#xD;
&#xD;
      The investigators want to examine, in a double-blind randomized placebo controlled parallel&#xD;
      study, the physiological effect of a dietary intervention with pyridoxamine in abdominally&#xD;
      obese persons.&#xD;
&#xD;
      A sub-study is implemented next to the clinical trial. The objective of the sub-study is to&#xD;
      measure the metabolization and kinetics of pyridoxamine in plasma and urine with UPLC-MS/MS.&#xD;
      The sub-study comprises of 5 additional healthy volunteers, with pyridoxamine as an oral&#xD;
      supplement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Actual">August 8, 2020</completion_date>
  <primary_completion_date type="Actual">January 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>Difference after 8 weeks of intervention</time_frame>
    <description>Assessed by hyperinsulinemic-euglycemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microvascular function</measure>
    <time_frame>Difference after 8 weeks of intervention</time_frame>
    <description>Assessed by contrast-enhanced ultrasound (CEUS) in skeletal muscle</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Abdominal Obesity Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Pyridoxamine (1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 1), three times daily during 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyridoxamine (2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 2), three times daily during 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be asked to consume dietary supplements containing placebo (amylum solani), three times daily during 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pyridoxamine</intervention_name>
    <arm_group_label>Pyridoxamine (1)</arm_group_label>
    <arm_group_label>Pyridoxamine (2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Abdominal obesity: Waist circumference for men should be above 102 cm and for women&#xD;
             above 88 cm.&#xD;
&#xD;
          -  Caucasian (because of skin fluorescence and capillary microscopy measurements)&#xD;
&#xD;
          -  Aged 18-75 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes (i.e. using anti-diabetic medication, fasting glucose &gt;7.0 mmol/L, HbA1c&#xD;
             &gt;6.5%).&#xD;
&#xD;
          -  Active or history of cardiovascular disease (e.g. stroke, coronary artery disease,&#xD;
             peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac&#xD;
             surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac&#xD;
             arrhythmias or sudden cardiac death)&#xD;
&#xD;
          -  Hyperlipidemia (defined as serum total cholesterol &gt; 8 mmol/L or TG &gt; 4 mmol/L)&#xD;
&#xD;
          -  Smoking (&gt;10 cigarettes per day)&#xD;
&#xD;
          -  High alcohol usage (&gt;4 U/day) or drug abuse&#xD;
&#xD;
          -  Use of medication known to influence glucose metabolism, vascular function (e.g.&#xD;
             glucocorticosteroids, NSAID's)&#xD;
&#xD;
          -  Higher grade hypertension (&gt; 179 mmHg SBP and/or &gt; 109 mmHg DBP) in order not to&#xD;
             expose subjects to unnecessary risks)&#xD;
&#xD;
          -  Known allergic reaction to ultrasound contrast-agent&#xD;
&#xD;
          -  Pulmonary or inflammatory disease&#xD;
&#xD;
          -  Kidney failure or electrolyte disorders&#xD;
&#xD;
          -  Use of dietary supplements or an investigational product within the previous month&#xD;
&#xD;
          -  Unstable body weight (no drastic changes in life style before or during the&#xD;
             intervention are allowed, this means no weight gain or loss &gt;3 kg in the last two&#xD;
             months)&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  No change in use of oral anticonceptiva or IUD (12 weeks prior of during the&#xD;
             intervention)&#xD;
&#xD;
          -  Unwillingness to give up being a blood donor (or having donated blood) from 8 weeks&#xD;
             prior to the start of the study and during the study&#xD;
&#xD;
          -  Insufficient knowledge of the Dutch language&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Casper G Schalkwijk, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6200MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

